Month: September 2020

NIET VOOR DISTRIBUTIE IN OF NAAR DE VERENIGDE STATENVAN AMERIKA, JAPAN, CANADA, AUSTRALIË, ZUID-AFRIKA OF ZWITSERLANDPersberichtGereglementeerde informatie – Voorkennis3 september 2020, 07:00u, Antwerpen (Berchem), België: VGP NV (‘VGP’ of ‘de Groep’), een toonaangevende Europese ontwikkelaar van hoogwaardig logistiek en semi-industrieel vastgoed, kondigt vandaag aan dat VGP Belgium NV (een 100% dochteronderneming van VGP NV en voorheen genaamd VGP MISV Comm.VA) met succes 929.153 bestaande aandelen in VGP (de ”Aandelen”) heeft geplaatst, wat overeenkomt met 4,51% van het uitstaande aandelenkapitaal van VGP, door middel van een versnelde private plaatsing (accelerated bookbuild) bij institutionele investeerders (de “Plaatsing”). De aandelen waren geplaatst aan een prijs van €117,50 per Aandeel, wat resulteert in...

PRESS RELEASE: REGULATED INFORMATION3 September 2020, 07:00 CEST            BIOCARTIS ANNOUNCES H1 2020 RESULTSMechelen, Belgium, 3 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces its business highlights and financial results for the first half of 2020, prepared in accordance with IAS 34 ‘Interim Financial Reporting’ as adopted by the European Union. Furthermore, the Company reinstates its outlook for the full year 2020.Commenting on the H1 2020 results, Herman Verrelst, Chief Executive Officer of Biocartis, reacted: “The global pandemic definitely left its marks, but we nevertheless delivered a 12% growth of overall commercial cartridge volumes in H1 2020. Supported by a loyal customer base and a swift recovery towards the end...

PERSBERICHT: GEREGLEMENTEERDE INFORMATIE3 september 2020, 07:00 CEST            BIOCARTIS KONDIGT H1 2020 RESULTATEN AANMechelen, België, 3 september 2020 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag zijn operationele hoogtepunten en financiële resultaten voor de eerste helft van 2020 aan, opgesteld in overeenstemming met IAS 34 IFRS ‘Tussentijdse Financiële Verslaggeving’ zoals aangenomen door de Europese Unie. Bovendien herintroduceert de Vennootschap ook zijn vooruitzichten voor het volledige jaar 2020.Herman Verrelst, Chief Executive Officer van Biocartis, reageerde als volgt op de H1 2020 resultaten: “De wereldwijde pandemie heeft zeker zijn sporen nagelaten, maar we hebben niettemin een groei gerealiseerd in H1 2020 van 12%...

New data further reinforce OCREVUS (ocrelizumab) as a highly effective treatment option offering a favourable and consistent benefit:risk profile, with high treatment persistence and adherenceInitiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populationsInitiation of Phase III clinical trial programme for fenebrutinib, an investigational medicine designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, which may offer novel approach to suppress disease activity and slow disease progression in MSNew Phase III data from SAkuraStar and SAkuraSky studies demonstrate reduced severity of relapses with ENSPRYNG (satralizumab), recently FDA-approved as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody...

Sanofi and GSK initiate Phase 1/2 clinical trial of COVID-19 adjuvanted recombinant protein-based vaccine candidatePre-clinical studies show promising safety and immunogenicity.Over 400 participants being enrolled in Phase 1/2 studyPending positive Phase 1/2 data, companies aim to move into Phase 3 by end of 2020Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021PARIS and LONDON – Sept. 3, 2020 – Sanofi and GSK today started the Phase 1/2 clinical trial for their adjuvanted COVID-19 vaccine. The vaccine candidate, developed in partnership by Sanofi and GSK, uses the same recombinant protein-based technology as one of Sanofi’s seasonal influenza vaccines with GSK’s established pandemic adjuvant technology.The Phase 1/2 clinical trial is a randomized, double...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWS AGENCIESTORONTO, Sept. 02, 2020 (GLOBE NEWSWIRE) — CANSTAR RESOURCES INC. (TSXV: ROX) (“Canstar Resources” or the “Company”) announces that, further to its press release dated August 26, 2020, it is amending the terms (the “Amendment”) of its proposed non-brokered private placement for aggregate gross proceeds of up to $2,000,000 (the “Offering”).Pursuant to the Amendment, Canstar Resources intends to complete the Offering in two tranches. The first tranche will consist of the sale of up to 4,761,905 units (“Part & Parcel Units”) at a price of $0.105 per Part & Parcel Unit, for gross proceeds of up to $500,000. Each Part & Parcel Unit will be comprised of one common share in the equity of the Company (each, a “Common Share”) and one Common...

HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) — Kayne Anderson MLP/Midstream Investment Company (the “Company”) (NYSE: KYN) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of August 31, 2020.As of August 31, 2020, the Company’s net assets were $783 million, and its net asset value per share was $6.19. As of August 31, 2020, the Company’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 641% and the Company’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 308%.As of August 31, 2020, equity and debt investments were 99% and 1%, respectively, of the Company’s long-term investments of $1.1...

HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) — Kayne Anderson Midstream/Energy Fund, Inc. (the “Fund”) (NYSE: KMF) today provided a summary unaudited statement of assets and liabilities and announced its net asset value and asset coverage ratios under the Investment Company Act of 1940 (the “1940 Act”) as of August 31, 2020. As of August 31, 2020, the Fund’s net assets were $295 million and its net asset value per share was $6.25. As of August 31, 2020, the Fund’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 496% and the Fund’s asset coverage ratio under the 1940 Act with respect to total leverage (debt and preferred stock) was 337%. As of August 31, 2020, equity and debt investments were 94% and 6%, respectively, of the Fund’s long-term investments of $396 million.  Long-term...

MELBOURNE, Australia and PALO ALTO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announced it has entered into a strategic collaboration agreement with Palo Alto-based Varian Medical Systems, to evaluate the use of advanced prostate cancer imaging within Varian’s radiation treatment planning platform.Under the terms of the agreement, the parties will leverage Telix’s extensive clinical data for imaging prostate-specific membrane antigen (PSMA) with positron emission tomography (PET) to potentially develop new image-guided treatment planning functions, automated analysis and artificial intelligence capabilities within Varian’s radiation treatment planning technology platforms. The goal of the collaboration is to ensure that the latest standard of care in prostate...